p53, estrogen and progesterone receptors in diagnostic curettage for endometrial adenocarcinoma and their correlation with morphological data and disease stage at hysterectomy

Sao Paulo Medical Journal

Volumn 121, Issue 4, 2003, Pages 163-166

  Leite Bonfitto, Vera Lúcia ^a   Lucci de Angelo Andrade, Liliana Aparecida ^a  

^a UNIVERSITY OF CAMPINAS   (Brazil)

Author keywords

Endometrial carcinoma; Estrogen receptor; p53; Progesterone receptor

Indexed keywords

AVIDIN; BIOTIN; ESTROGEN RECEPTOR; PEROXIDASE; PROGESTERONE RECEPTOR; PROTEIN P53; TUMOR MARKER;

ADULT; ADVANCED CANCER; AGED; ARTICLE; CANCER GRADING; CANCER STAGING; CONTROLLED STUDY; CORRELATION ANALYSIS; CURETTAGE; DIAGNOSTIC PROCEDURE; DIAGNOSTIC VALUE; DISEASE ASSOCIATION; ENDOMETRIUM CARCINOMA; FEMALE; FREQUENCY ANALYSIS; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; HYSTERECTOMY; IMMUNOHISTOCHEMISTRY; INTERMETHOD COMPARISON; MAJOR CLINICAL STUDY; MEDICAL RECORD; MORPHOLOGY; PREDICTION; PROGNOSIS; PROTEIN EXPRESSION; RETROSPECTIVE STUDY; STATISTICAL SIGNIFICANCE;

EID: 0141891356     PISSN: 15163180     EISSN: None     Source Type: Journal    
DOI: 10.1590/s1516-31802003000400005     Document Type: Article

References (28)

1. Ball HG, Blessing JA, Lentz SS, Mutch DG. A phase II trial of paclitaxel in patients with advanced or recurrent adenocarcinoma of the endometrium: a Gynecologic Oncology Group study. Gynecol Oncol 1996;62(2):278-81.
2. Parker SL, Tong T, Bolden S, Wingo PA. Cancer statistics, 1996. CA Cancer J Clin 1996;46(1):5-27.
3. Brasil. Ministério da Saúde, Instituto Nacional do Câncer/Inca, Coordenação de Programas de Controle do Câncer. [Coordination Office for Cancer Control Programs]. Pró-câncer no Brasil: dados dos registros de base hospitalar. Rio de Janeiro: Pró-onco; 1993.
4. Pedro AO, Pinto-Neto AM, Costa-Paiva LHS, Borges MH, Lane E. A neoplasia maligna como causa de óbita feminino no Complexo Hospitalar da Unicamp: un aspecto de transição epidemiológica. Rev Bras Ginecol Obstet 1996;18(4):349-53.
5. Kurman RJ, Zaino RJ, Norris HJ. Endometrial carcinoma. In: Kurman RJ, editor. Blaustein's pathology of the female genital tract. 4th ed. Berlin: Springer-Verlag; 1994. p.439-86.
6. Gompel C, Silverberg SG. The Corpus Uteri. In: Gompel C, Silverberg SG, editors. Pathology in Gynecology and Obstetrics. 4th ed. Philadelphia: JB Lippincott Company; 1994. p.163-283.
7. Hendrickson MR, Kempson RL. The Uterine Corpus. In: Sternberg SS, Antonioli DA, Mills SE, Carter D, Oberman HA, editors. Diagnostic Surgical Pathology. 2nd ed. Philadelphia: Lippincott-Raven Publishers; 1994. p.2091-193.
8. Berchuck A, Kohler MF, Marks JR, Wiseman R, Boyd J, Bast RC. The p53 tumor suppressor gene frequently is altered in gynecologic cancers. Am J Obstet Gynecol 1994;170(1 Pt 1):246-52.
9. Geisler JP, Wiemann MC, Zhou Z, Miller GA, Geiler HE. p53 as a prognostic indicator in endometrial cancer. Gynecol Oncol 1996;61(2):245-8.
10. Burton JL, Stewart RL, Healtley MK, Royds JA, Wells M. p53 expression, p21 expression and the apoptotic index in endometrial endometrial adenocarcinoma. Histopathology 1999;35(3):221-9.
11. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol 1983;15(1):10-7.
12. Honda T, Kato H, Imamura T, et al. Involvement of p53 gene mutation in human endometrial carcinomas. Int J Cancer 1993;53(6):963-7
13. Scully RE, Bonfiglio TA, Kurman RJ, Silverberg SG, Wilkinson EJ. Histological Typing of Female Genital Tract Tumours: in collaboration with Pathologists in 10 Countries. 2nd ed. Heibelberg: Springer-Verlag; 1994.
14. Shepherd JH. Revised FIGO staging for gynaecological cancer. Br J Obstet Gynaecol 1989;96(8):889-92.
15. Burton JL, Wells M. Recent advances in the histopathology and molecular pathology of carcinoma of the endometrium. Histopathology 1998;33(4):297-303.
16. Ioffe OB, Papadimitriou JC, Drachenberg CB. Correlation of proliferation indices, apoptosis, and related oncogene expression (bcl-2 and c-erbB-2) and p53 in proliferative, hyperplastic, and malignant endometrium. Hum Pathol 1998;29(10):1150-9.
17. Noumoff JS, Menzin A, Mikuta J, et al. The ability to evaluate prognostic variables on frozen section in hysterectomies performed for endometrial carcinoma. Gynecol Oncol 1991;42(3)202-8.
18. Kounelis S, Kapranos N, Kouri E, Coppola D, Papadaki H, Jones MW. Immunohistochemical profile of endometrial adenocarcinoma: a study of 61 case and review of the literature. Mod Pathol 2000;13(4):379-88.
19. Mutter GL. Endometrial intraepithelial neoplasia (EIN): will it bring order to chaos? The Endometrial Collaborative Group. Gynecol Oncol 2000;76(3):287-90.
20. Lax SF, Kendall B, Tashiro H, Slebos RJ, Hedrick I. The frequency of p53, K-ras mutations, and microsatellite instability differs in uterine endometrial and serous carcinoma evidence of distinct molecular genetic pathway. Cancer 2000;88(4):814-24.
21. Fernando SSE, Wu X, Perera LS. p53 Overexpression and Steroid Hormone Receptor Status in Endometrial Carcinoma. Int J Surg Pathol 2000;8(3):213-22.
22. Hamel NW, Sebo TJ, Wilson TO, et al. Prognostic value of p53 and proliferating cell nuclear antigen expression in endometrial carcinoma. Gynecol Oncol 1996;62(2):192-8.
23. Ito K, Watanabe K, Nasim S, et al. Prognostic significance of p53 overexpression in endometrial cancer. Cancer Res 1994;54(17):4667-70.
24. Taskin M, Lallas TA, Barber HR, Shevchuk MM. bcl-2 and p53 in endometrial adenocarcinoma. Mod Pathol 1997;10(7):728-34.
25. Ozsaran AA Tüker S, Dikmen Y, et al. p53 staining as a prognostic indicator in endometrial carcinoma. Eur J Gynaecol Oncol 1999;20(2):156-9.
26. Elhafey AS, Papadimitriou JC, El-Hakim MS, et al. Computerized image analysis of p53 and proliferating cell nuclear antigen expression in benign, hyperplastic, and malignant endometrium. Arch Pathol Lab Med 2001;125(7):872-9.
27. Ambros RA, Vigna PA, Figge J, et al. Observations on tumor and metastatic suppressor gene status in endometrial carcinoma with particular emphasis on p53. Cancer 1994;73(6):1686-92.
28. Rose PG. Endometrial carcinoma. N Engl J Med 1996;335(9):640-9.